Background The antiepidermal growth factor receptor (antiEGFR) monoclonal antibodies
cetuximab and panitumumab have good clinical activity in about 10% of patients with …

Introduction In gene expression experiments, hormone receptor (HR)-positive/human
epidermal growth factor-2 (HER2)-positive tumors generally cluster within the luminal B subset; …

… (TKIs) in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small-…
Therefore, the aim of this study was to assess the overall survival (OS) of advanced EGFR-…

… One such molecular target is human epidermal growth factor receptor 2 (HER2), also known
… Therefore, our study objective was to determine whether HER2 is a prognostic biomarker in …

… Urinary epidermal growth factor (uEGF) is involved in kidney tissue integrity, with a … In this
prospective cohort study, RTR with a functioning allograft ≥1-year were recruited and followed-…

Background Human epidermal growth factor receptor-2 (HER2) is overexpressed in 20–25%
of breast cancers. Complete eradication of disease following neoadjuvant therapies and …

… Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in …
A prospective, observational cohort study was designed and initiated to provide real-world …

Background The magnitude of benefit of trastuzumab for the treatment of advanced HER2-positive
breast cancer varies widely. In this retrospective study, we investigated the …

… in a randomised study. Considering the potential ethical implication, a randomised comparative
study can be challenging. Here we report a matched-cohort study comparing patients …

… Human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth
factor receptor family, is encoded by a gene (HER2 or ERBB2) located on the long arm of …